FOR IMMEDIATE RELEASE – July 1, 2019

Southlake Equity Group announced today that it exited its investment in Titan Spine, Inc. when Titan was sold to a publicly-traded medical device company. The sale closed on June 27.

Southlake Equity Group led growth-equity investments in Titan Spine that were made in 2016 and 2018. Titan Spine, Inc. is a surface technology company focused on the design and manufacture of interbody fusion devices for the spine. Headquartered in Mequon, Wisconsin, Titan Spine markets a full line of endoskeleton interbody devices featuring its proprietary textured surface in the U.S., Europe, and Australia. During the period of Southlake’s investment in Titan, the company grew sales by nearly 60 percent and launched its newest line of Nanotech
endoskeleton products.

Tom Keene, Managing Partner at Southlake Equity Group, said: “It has been an absolute pleasure to partner with the management team of Titan Spine since 2016. We wish the management team continued success in driving improvements in patient outcomes as Titan’s unique technology continues to penetrate the spine market.”

About Southlake Equity Group

Southlake Equity Group is a private investment firm that makes equity and debt investments in American middle market companies in manufacturing, distribution and service industries. The firm backs its belief in the ingenuity, innovation and productivity of the American entrepreneur, business manager and worker with patient, non-institutional capital that helps companies grow and become industry leaders.